When FDA receives a new drug application with a single pivotal trial plus confirmatory evidence offered in support of accelerated approval, for example Pfizer Inc.’s orphan drug Vyndaqel (tafamidis meglumine) for familial amyloid polyneuropathy, the agency sets a high standard for statistical significance, such as a p-value of less than 0.01, an FDA official said.
While stressing that there is not a hard-and-fast rule, Russell Katz, director of FDA’s Division of Neurology Products, told the...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?